TECH · BIO-TECHNE Corp · Executive Compensation
Market Cap
$11.33B
Shares
156.82M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Kim Kelderman | President and CEO | $8,151,181 |
| James T. Hippel | Executive Vice President and CFO | $7,027,382 |
| William Geist | President, Protein Sciences | $3,139,299 |
| Matthew McManus | President, Diagnostics and Spatial Biology | $2,846,619 |
| Shane Bohnen | Senior Vice President and General Counsel | $1,980,732 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Kim Kelderman | President and CEO Former President, Diagnostics and Genomics | $6,852,495 |
| Charles Kummeth | Former President and CEO | $6,792,945 |
| James T. Hippel | Executive Vice President and CFO | $5,202,632 |
| William Geist | President, Protein Sciences | $3,647,219 |
| Matthew McManus | President, Diagnostics and Genomics | $1,994,642 |
| Shane Bohnen | Senior Vice President and General Counsel | $1,455,793 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Charles Kummeth | Former President and CEO | $30,584,644 |
| James T. Hippel | Executive Vice President and CFO | $3,441,870 |
| Kim Kelderman | President and CEO Former President, Diagnostics and Genomics | $2,605,711 |
| William Geist | President, Protein Sciences | $2,333,628 |
| Brenda Furlow | Former Executive Vice President and General Counsel | $1,888,581 |
| Shane Bohnen | Senior Vice President and General Counsel | $1,044,244 |
| Matthew McManus | President, Diagnostics and Genomics | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Charles Kummeth | Former President and CEO | $15,370,549 |
| James T. Hippel | Executive Vice President and CFO | $4,436,029 |
| David Eansor | Former President, Protein Sciences | $3,209,406 |
| Brenda Furlow | Former Executive Vice President and General Counsel | $2,958,226 |
| Kim Kelderman | President and CEO Former President, Diagnostics and Genomics | $2,947,367 |
| William Geist | President, Protein Sciences | $2,564,286 |
| Shane Bohnen | Senior Vice President and General Counsel | — |
| Matthew McManus | President, Diagnostics and Genomics | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Charles Kummeth | President and CEO | $15,889,896 |
| David Eansor | Former President, Protein Sciences | $6,438,528 |
| Brenda Furlow | Former Executive Vice President and General Counsel | $4,472,676 |
| James T. Hippel | Executive Vice President and CFO | $3,157,058 |
| Kim Kelderman | President, Diagnostics and Genomics | $2,175,311 |
| Shane Bohnen | Senior Vice President and General Counsel | — |
| William Geist | President, Protein Sciences | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Charles Kummeth | President and CEO | $11,483,782 |
| James T. Hippel | Executive Vice President and CFO | $3,157,058 |
| David Eansor | Former President, Protein Sciences | $2,685,749 |
| Kim Kelderman | President, Diagnostics and Genomics | $2,175,311 |
| Brenda Furlow | Executive Vice President and General Counsel | $1,823,659 |
| William Geist | President, Protein Sciences | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Charles Kummeth | President and CEO | $11,011,138 |
| James T. Hippel | Senior Vice President of Finance and CFO | $2,757,790 |
| David Eansor | President, Protein Sciences | $2,323,038 |
| Kim Kelderman | President, Diagnostics and Genomics | $1,565,373 |
| Brenda Furlow | Senior Vice President – | $1,483,773 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Charles Kummeth | President and CEO | $9,664,874 |
| James T. Hippel | Senior Vice President of Finance and CFO | $2,448,887 |
| David Eansor | President, Protein Sciences | $1,591,282 |
| General Counsel | — | $1,218,202 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Steve Crouse | President, Diagnostics and Spatial Biology Segment | Appointed | 2026-02-11 |
| Amy Herr | independent director | Appointed | 2025-02-05 |
Key facts
CIK
842023
CUSIP
09073M104
13F (30d)
310 filings
309 filers
Visit website
Investor relations